Overview

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Status:
Not yet recruiting
Trial end date:
2023-06-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare donanemab to aducanumab on amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company